Navigation Links
XE-2100L

ProductsXE-2100L
Company Sysmex America, Inc.
Item XE-2100L
Features Network capability allows for easy integration into a computer network system, provides excellent separation or normal as well as abnormal cell populations by patented new technology of fluorescent reagents, employs a reliable and economical semiconductor laser as the light source for the flow cytometry system, exhibits high performances with a throughput of up to 150 samples/hour, higher productivity is acquired by connecting two units with optional TCM software, more efficient reagent management or more enhanced analysis can be realized by upgrade-software products (XE pro series).
Description The XE-2100L automated hematology analyzer features new hematology parameters as NRBC, IRF, and HPC that offer valuable and accurate clinical information.
Info Sysmex America, Inc.Call Sysmex America, Inc. to buy products (US and Canada only; other locations use number below) USACanada1-866-394-3469

Customer Service: 1-800-379-7639

Related medicine products :

1. Coulter LH 755 Hematology Workcell
2. Coulter LH 750 Hematology Analyzer
3. Coulter HmX
4. Coulter MAXM
5. Coulter AcT 5diff OV
6. Coulter EPICS XL
7. Coulter EPICS XL-MCL
8. COULTER AcT 5diff CP (Cap Pierce)
9. COULTER AcT 5diff OV (Open Vial)
TAG:
IMMULITE 2000 assays are designed for use with the IMMULITE 2000, a high-throughput, continuous random access immunoassay analyzer. IMMULITE 2000 offers testing efficiency through centralization, and
...EIATM IGF-I kit is a two-site ELISA for the quanti...-I (IGF-I) in serum or plasma. The assay uses a hi...rotiter wells and a high affinity monoclonal antib... sample pre-treatment replaces acid/ethanol extrac...
For The Detection Of Serum C-Peptide Levels.,Clinical Uses Of C-Peptide Measurement:, Evaluating patients with fasting hypoglycemia , Assisting in the classification of diabetes mellitus , D
... IR Excimer Laser System is designed to bring Cust...ife and provide the flexibility to treat patients ..., ,Technologies like Active Trak 3-D eye track...VSS), Variable Repetition Rate (VRR), and Iris Reg...
Medicine Products:
(Date:11/21/2008)...general membership of the Medical,Advertising Hal... their Annual,Awards Dinner to be held February 1...me Achievement Award will also be given. , ...ll of Fame are: , Ronald Pantello, who began hi...Sudler & Hennessey. In 1980 he left Sudler &am...
(Date:11/21/2008)...ases production of neural stem cells , ,...s in mice, exercise appears to reverse the decline...n with aging, Taiwanese researchers report. , T...to stave off aging appears to be due to exercise,s...ial for the production of new brain cells. , "...
(Date:11/21/2008)...e/ -- A prestigious group of physicians, nurses, a...iamsburg, VA on March 27-29, 2009 at the Williamsb... on cutting-edge therapeutic protocols, novel diag...s that impact patient care. The full program, facu...s available at www.bioconferences.com/wh , ,...
(Date:11/21/2008)...ty of Texas M. D. Anderson Cancer Center marked th... breast cancer in Panama through the Partnership f...ricas today at an event with Laura Bush, the First... Torrijos, the First Lady of Panama. , Joining...artment of State and Susan G. Komen for the Cure w...
Breaking Medicine News(10 mins):Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:Exercise Keeps the Brain Young 2Health News:17th Annual Congress on Women's Health Convenes March 27-29, 2009 in Williamsburg, VA 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research extends to Panama 2
...a Swedish doctor involving more than 65, 000 per...of blood sugar and the risk of developing cancer//...er, Sweden and team, who examined data from 31,304...search. The subjects had previously participated...
...a higher body mass index (BMI) tend are less likel...tion for an ischemic stroke// , according to a rep...lood to a part of the brain is blocked or reduced ...t be delivered to brain tissue. Obesity and excess...
...d dean of University of Massachusetts Medical Scho...o health reasons//. It was reported that he has de...sible for the merger of state hospital and the pri...et up the $ 100 million research lab there. In 198...
...ently accounts for one-third of the global TB burd...tion// infected by the TB bacillus. Every year, ...0 die from it, resulting in 1,000 deaths every day...than other infectious diseases, it has been report...
Other Medicine News:Health News:Beware of High Sugar Levels Even If You are Not Diabetic 2Health News:Stroke Patients With High BMI Less Likely to Be Discharged After Hospitalization 2Health News:TB Incidence on Rise Among Children in Tamil Nadu, Maharashtra 2
(Date:11/19/2008)...THOUSAND OAKS, Calif., Nov. 19 /PRNewswire-FirstCa...e Takeda Oncology Company, a subsidiary of,Takeda... announced that,enrollment in the Phase 3 MONET1 ...on with paclitaxel and carboplatin for the first-l...cer (NSCLC) has been temporarily suspended,follow...
(Date:11/19/2008)...-Triggers $5 Million Payment from Roche- , , ...- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) t... goal for its Phase 2 trial of R3487/MEM 3454, its...tive impairment associated with schizophrenia (CIA...e Phase 2 trial, triggering a $5.0 million payment...
(Date:11/18/2008)...American Lung Association,s 2008 Faces of Influenz...lies immunized against influenza; Mother and Gold ..., WASHINGTON, Nov. 18 While 78 ...nfluenza a severe and potentially life-threatening...is likely their families will get vaccinated this ...
(Date:11/12/2008)... NEW YORK, Nov. 12 A... edition of Cell will help answer the,question, wh...ressing questions in the medical research into,Par...s in the brain to die,in the first place. Answerin...use there are two nearly identical types of brain ...
Breaking Medicine Technology:Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6A Window Into Parkinson's Disease 2Antares Management Solutions Selects Hyland Softwares OnBase 13993 1Antares Management Solutions Selects Hyland Softwares OnBase 13993 2Schering Plough Announces Filing of U S Application for OTC ZEGERID 28R 29 3853 1Schering Plough Announces Filing of U S Application for OTC ZEGERID 28R 29 3853 2Schering Plough Announces Filing of U S Application for OTC ZEGERID 28R 29 3853 3Wildwood Organics Introduces Probiotic Soymilk 28TM 29 13990 1Wildwood Organics Introduces Probiotic Soymilk 28TM 29 13990 2Totality of Available Data Reaffirms PROCRIT 28R 29 28Epoetin alfa 29 Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy 1495 1Totality of Available Data Reaffirms PROCRIT 28R 29 28Epoetin alfa 29 Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy 1495 2Totality of Available Data Reaffirms PROCRIT 28R 29 28Epoetin alfa 29 Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy 1495 3Totality of Available Data Reaffirms PROCRIT 28R 29 28Epoetin alfa 29 Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy 1495 4Totality of Available Data Reaffirms PROCRIT 28R 29 28Epoetin alfa 29 Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy 1495 5Totality of Available Data Reaffirms PROCRIT 28R 29 28Epoetin alfa 29 Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy 1495 6